CoChat

The first echinocandin: caspofungin: Das erste Echinocandin: Caspofungin

Cornely, O.A., Schmitz, Karina, Aisenbrey, Sabine · 2002 · Mycoses
Cited by 53

The DOI matches its Crossref record; 2 of the 2 references it cites were found in a registry or an index.

Abstract

Summary. The antifungal agent caspofungin is the first echinocandin that has been approved in the US and in Europe for treatment of invasive aspergillosis in adult patients who are refractory to or intolerant of conventional amphotericin B, its lipid‐based formulations, and/or itraconazole. It is given as a 70 mg loading dose and a 50 mg daily maintainance dose as a one hour infusion. Due to low intestinal absorption an oral formulation has not been developed. Caspofungin is active against Candida spp. and Aspergillus spp. by inhibition the synthesis of β‐(1,3)‐D‐glucan, a cell wall component. The drug is inactive against Cryptococcus spp., Fusarium spp., Trichosporon spp., Rhizopus spp., and Pseudoallescheria spp. In invasive aspergillosis caspofungin resulted in higher response rates compared to a historic control under standard therapy. Efficacy data on persistently febrile neutropenic patients are pending. In several multicenter randomised double blind trials on candida infections caspofungin proved to be at least non‐inferior to standard therapies. Reports of combination therapy or highly effective antifungal treatment (HEAT) in limited patient numbers are promising. New trials of combination therapy are warranted. Zusammenfassung. Caspofungin ist das erste Antimykotikum aus der Klasse der Echinocandine. Es ist in den USA und in Europa zugelassen zur Therapie invasiver Aspergillosen erwachsener Patienten, die auf eine Standardtherapie nicht ansprechen oder diese nicht vertragen. Caspofungin wird am ersten Tag mit 70 mg dosiert und danach mit einer Erhaltungsdosis von 50 mg als einstündige Infusion verabreicht. Wegen seiner geringen enteralen Resorption ist eine orale Formulierung nicht entwickelt worden. Caspofungin ist wirksam gegen Candida spp. und Aspergillus spp. durch die Inhibition der Synthese des β‐(1,3)‐D‐Glucans, das ein Bestandteil der Zellwand ist. Die Substanz ist unwirksam gegenüber Cryptococcus spp., Fusarium spp., Trichosporon spp., Rhizopus spp., und Pseudoallescheria spp. In der Therapie der invasiven Aspergillose war Caspofungin effektiver als Standardtherapien in einem historischen Vergleichskollektiv. Daten zur Effektivität persistierend febriler neutropenischer Patienten werden erwartet. In einigen randomisierten multizentrischen doppel‐blinden Studien zu Candida‐Infektionen zeigte sich Caspofungin zumindest als nicht‐unterlegen im Vergleich zu Standardtherapien. Berichte über Kombinationstherapien, die sog. hocheffektive antimykotische Therapie (HEAT) begrenzter Patientenzahlen sind vielversprechend. Weiter führende Kombinationsstudien sind erforderlich.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1111/j.1439-0507.2002.tb04771.x

Cites

2 of 2 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 2 references

Cited by

See all 53

Metadata

Authors
Cornely, O. A., Schmitz, K., & Aisenbrey, S.
Venue
Mycoses
Publisher
Wiley
Published
2002-04
Volume
45
Issue
S3
Pages
56-60
ISSN
  • 0027-5557 (ISSN-L)
  • 0933-7407
  • 1439-0507
OpenAlex
W2147459045
Cited by
53
References
2
FWCI
2.83
Type
journal article
Language
en
Open access
closed

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: The first echinocandin: caspofungin: Das erste Echinocandin: Caspofungin. https://app.cochat.ai/papers/10.1111/j.1439-0507.2002.tb04771.x
The paper
Cornely, O. A., Schmitz, K., & Aisenbrey, S. (2002). The first echinocandin: caspofungin: Das erste Echinocandin: Caspofungin. Mycoses. https://doi.org/10.1111/j.1439-0507.2002.tb04771.x

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.